ClinicalTrials.gg
CompletedNCT03878264Updated Jun 11, 2019

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

A Phase 1 interventional study of CORT118335 Oral and 14C-CORT118335 intravenous in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-11.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a single oral dose of CORT118335 in healthy male participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years of age for Part 1 and 30 to 65 years of age for Part 2
  • of 18.0 to 30.0 kg/m\^2
  • Provide written
  • Have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) for Part 2
  • Adhere to the requirements.

Exclusion criteria

Exclusion Criteria:

  • Have received any medicine in a clinical research study within the previous 3 months or CORT118335 at any time
  • Employees or immediate family members of employees of the study site or Sponsor
  • Have a pregnant partner
  • History of abuse of any drug or alcohol, or regularly consume more than 21 units alcohol/week
  • Smokers or users of e-cigarettes and nicotine replacement products within the last 6 months
  • Occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017; greater than background radiation exposure from other sources exceeding 5 milliSieverts (mSv) in the last 12 months or 10 mSv in the last 5 years
  • abnormal results of clinical laboratory safety tests, , or measurement of heart rate and blood pressure
  • History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, neurological, or gastrointestinal disease
  • History and/or symptoms of adrenal insufficiency or any condition that could be aggravated by blockade (e.g., an disease; allergy requiring treatment)
  • Donation or loss of greater than 400 mL of blood within the past 3 months
  • Has consumed liquorice or other glycyrrhetic acid derivatives regularly in the past 6 months
  • Are taking, or have taken, any prescribed, over-the-counter drug or vitamins/herbal remedies within 14 days (longer restrictions apply for some medicines).

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Part 1

    On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.

    Drug: CORT118335 Oral · Drug: 14C-CORT118335 intravenous

  • Experimental
    Part 2

    On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.

    Drug: 14C-CORT118335 oral

Interventions

  • CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration

    Also known as: Treatment A

  • Drug14C-CORT118335 intravenous

    14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C

    Also known as: Treatment B

  • Drug14C-CORT118335 oral

    14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C

    Also known as: Treatment C

06

What researchers measure

Primary outcomes

  1. Absolute Oral Bioavailability (F) of CORT118335

    Time frame: Predose and at pre-specified time points up to Day 12

  2. Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT118335

    Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)

  3. Mass Balance Recovery in Urine After a Single Oral Dose of 14C-CORT118335

    Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)

  4. Mass Balance Recovery in Feces After a Single Oral Dose of 14C-CORT118335

    Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)

Secondary outcomes

  1. Pharmacokinetics (PK) of Total Radioactivity after Oral Dosing: Peak Plasma Concentration (Cmax)

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  2. PK of Total Radioactivity in Plasma after Oral Dosing: Time from Dosing to Cmax (tmax)

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  3. PK of Total Radioactivity after Oral Dosing: Area Under the Plasma Concentration-time Curve from Zero Time to Time of the Last Measurable Concentration (AUC0-last)

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  4. PK of Total Radioactivity in Plasma after Oral Dosing: Apparent Elimination Half-life (t1/2)

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  5. PK of Total Radioactivity in Plasma after Oral Dosing: Mean Residence Time (MRT)

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  6. PK of Plasma CORT118335 after Oral Dosing: Cmax

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  7. PK of Plasma CORT118335 after Oral Dosing: Tmax

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  8. PK of Plasma CORT118335 after Oral Dosing: AUC0-last

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  9. PK of Plasma CORT118335 after Oral Dosing: MRT

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  10. PK of Plasma 14C-CORT118335 after IV Dosing: Cmax

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  11. PK of Plasma 14C-CORT118335 after IV Dosing: AUC0-last

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  12. PK of Plasma 14C-CORT118335 after IV Dosing: t1/2

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  13. PK of Plasma 14C-CORT118335 after IV Dosing: Total Clearance (CL)

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  14. PK of Plasma 14C-CORT118335 after IV Dosing: MRT

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  15. PK of Total Radioactivity in Plasma after IV Dosing: Cmax

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  16. PK of Total Radioactivity in Plasma after IV Dosing: AUC0-last

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  17. PK of Total Radioactivity in Plasma after IV Dosing: t1/2

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  18. PK of Total Radioactivity in Plasma after IV Dosing: CL

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  19. PK of Total Radioactivity in Plasma after IV Dosing: MRT

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  20. PK in Plasma after IV Dosing: AUC0-last for 14C-CORT118335 / AUC0-last for Total Radioactivity

    Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing

  21. Distribution of Total Radioactivity into Red Blood Cells after Oral Dosing

    Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing

  22. Number of CORT118335 Metabolites Accounting for >10% of Total Radioactivity Detected in Plasma, Urine, and Feces

    Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)

  23. Percentage of Participants with One or More Adverse Events

    Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Mar 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2019
First posted
Mar 18, 2019
StartActual
Aug 6, 2018
Primary completionActual
Mar 24, 2019
CompletionActual
Mar 24, 2019
Last update
Jun 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03878264
Responsible party
Sponsor
First posted
Mar 18, 2019
Start date
Aug 6, 2018
Primary completion
Mar 24, 2019
Completion
Mar 24, 2019
Last update
Jun 11, 2019

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion